UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center

Journal of endocrinological investigation, 2023-11, Vol.46 (11), p.2399-2409

2023

Volltextzugriff (PDF)

KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S180-S180

2017

Volltextzugriff (PDF)

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine

Lung cancer (Amsterdam, Netherlands), 2011-02, Vol.71 (2), p.191-198

2011

Volltextzugriff (PDF)

Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi38

2017

Volltextzugriff (PDF)

Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single‐institution, retrospective case series

British journal of dermatology (1951), 2017-02, Vol.176 (2), p.507-509

2017

Volltextzugriff (PDF)

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

Annals of oncology, 2006-04, Vol.17 (4), p.668-675

2006

Volltextzugriff (PDF)

Safety Profile of Tyrosine Kinase Inhibitors Approved for Gastrointestinal Stromal Tumors: Analysis from the European Spontaneous Adverse Event Reporting System

Drug safety, 2022-10, Vol.45 (10), p.1157-1158

2022

Volltextzugriff (PDF)

Safety Profile of Tyrosine Kinase Inhibitors Used in Non-Small- Cell Lung Cancer: An Analysis from The Italian Pharmacovigilance Database

Drug safety, 2022-10, Vol.45 (10), p.1158-1158

2022

Volltextzugriff (PDF)

2050 - KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S180-S180

2017

Volltextzugriff (PDF)

58PD NANOSTRING MULTIPLE TARGET PROFILING IDENTIFIES AEG-1 AS AN ESSENTIAL PREDICTOR OF ERLOTINIB OUTCOME IN EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S31-S31

2011

Volltextzugriff (PDF)

Immunotherapeutic Advances for NSCLC

Biologics, 2021-01, Vol.15, p.399-417

2021

Volltextzugriff (PDF)

EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S450-S451

2022

Volltextzugriff (PDF)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

Lung cancer (Auckland), 2017-01, Vol.8, p.109-125

2017

Volltextzugriff (PDF)

Patients' and physicians' interpretation of chemotherapy‐induced peripheral neurotoxicity

Journal of the peripheral nervous system, 2019-03, Vol.24 (1), p.111-119

2019

Volltextzugriff (PDF)

Weight loss in obese children carrying the proopiomelanocortin R236G variant

Journal of endocrinological investigation, 2006-03, Vol.29 (3), p.226-230

2006

Volltextzugriff (PDF)

P1.03-14 HLA-E and FAT1 in Head and Neck and Lung Cancer. The Effect of Osimertinib or Olmutinib with Artesunate (Dihydroartemisinin)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S422-S423

2019

Volltextzugriff (PDF)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

Drug design, development and therapy, 2017, Vol.11, p.2047-2063

2017

Volltextzugriff (PDF)

Predicting the outcome of chemotherapy for lung cancer

Current opinion in pharmacology, 2006-08, Vol.6 (4), p.323-331

2006

Volltextzugriff (PDF)

P2.03-15 Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S721-S722

2018

Volltextzugriff (PDF)

Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP)

Annals of oncology, 2016-10, Vol.27, p.vi424-vi424

2016

Volltextzugriff (PDF)

Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e18504-e18504

2011

Volltextzugriff (PDF)

EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7610-7610

2010

Volltextzugriff (PDF)

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going

Current opinion in oncology, 2006-03, Vol.18 (2), p.135-143

2006

Volltextzugriff (PDF)

Targeting PD-1/PD-L1 in lung cancer: current perspectives

Lung cancer (Auckland), 2015-01, Vol.6 (default), p.55-70

2015

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(162)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center

KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine

Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer

Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single‐institution, retrospective case series

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study

Safety Profile of Tyrosine Kinase Inhibitors Approved for Gastrointestinal Stromal Tumors: Analysis from the European Spontaneous Adverse Event Reporting System

Safety Profile of Tyrosine Kinase Inhibitors Used in Non-Small- Cell Lung Cancer: An Analysis from The Italian Pharmacovigilance Database

2050 - KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer

58PD NANOSTRING MULTIPLE TARGET PROFILING IDENTIFIES AEG-1 AS AN ESSENTIAL PREDICTOR OF ERLOTINIB OUTCOME IN EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC)

Immunotherapeutic Advances for NSCLC

EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

Patients' and physicians' interpretation of chemotherapy‐induced peripheral neurotoxicity

Weight loss in obese children carrying the proopiomelanocortin R236G variant

P1.03-14 HLA-E and FAT1 in Head and Neck and Lung Cancer. The Effect of Osimertinib or Olmutinib with Artesunate (Dihydroartemisinin)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

Predicting the outcome of chemotherapy for lung cancer

P2.03-15 Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC

Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP)

Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma

EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going

Targeting PD-1/PD-L1 in lung cancer: current perspectives

Suchergebnisse filtern